These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial. Højsgaard Chow H; Talbot J; Lundell H; Gøbel Madsen C; Marstrand L; Lange T; Mahler MR; Buhelt S; Holm Hansen R; Blinkenberg M; Romme Christensen J; Soelberg Sørensen P; Rode von Essen M; Siebner HR; Sellebjerg F Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34429340 [TBL] [Abstract][Full Text] [Related]
23. Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis: From the MS-STAT Randomized Controlled Trial. Williams TE; Holdsworth KP; Nicholas JM; Eshaghi A; Katsanouli T; Wellington H; Heslegrave A; Zetterberg H; Frost C; Chataway J Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35031587 [TBL] [Abstract][Full Text] [Related]
24. Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: A systematic review and meta-analysis. Ning L; Wang B PLoS One; 2022; 17(9):e0274565. PubMed ID: 36103562 [TBL] [Abstract][Full Text] [Related]
25. Neurofilament light chain as a biomarker of meningoencephalitis of unknown etiology in dogs. Yun T; Koo Y; Chae Y; Lee D; Kim H; Kim S; Chang D; Na KJ; Yang MP; Kang BT J Vet Intern Med; 2021 Jul; 35(4):1865-1872. PubMed ID: 34114244 [TBL] [Abstract][Full Text] [Related]
26. High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS. Thebault S; R Tessier D; Lee H; Bowman M; Bar-Or A; Arnold DL; L Atkins H; Tabard-Cossa V; Freedman MS Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):e598. PubMed ID: 31516913 [TBL] [Abstract][Full Text] [Related]
27. CSF neurofilament light chain testing as an aid to determine treatment strategies in MS. Reyes S; Smets I; Holden D; Carrillo-Loza K; Christmas T; Bianchi L; Ammoscato F; Turner B; Marta M; Schmierer K; Giovannoni G; Gnanapavan S Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32826298 [TBL] [Abstract][Full Text] [Related]
30. Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis. Camara-Lemarroy C; Silva C; Gohill J; Yong VW; Koch M Eur J Neurol; 2023 Jan; 30(1):187-194. PubMed ID: 36214614 [TBL] [Abstract][Full Text] [Related]
31. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Novakova L; Zetterberg H; Sundström P; Axelsson M; Khademi M; Gunnarsson M; Malmeström C; Svenningsson A; Olsson T; Piehl F; Blennow K; Lycke J Neurology; 2017 Nov; 89(22):2230-2237. PubMed ID: 29079686 [TBL] [Abstract][Full Text] [Related]
32. Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3. Li QF; Dong Y; Yang L; Xie JJ; Ma Y; Du YC; Cheng HL; Ni W; Wu ZY Mol Neurodegener; 2019 Nov; 14(1):39. PubMed ID: 31684998 [TBL] [Abstract][Full Text] [Related]
33. A comparative study of CSF neurofilament light and heavy chain protein in MS. Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999 [TBL] [Abstract][Full Text] [Related]
34. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort. Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051 [TBL] [Abstract][Full Text] [Related]
35. Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis. Bermel RA; Fedler JK; Kaiser P; Novalis C; Schneebaum J; Klingner EA; Williams D; Yankey JW; Ecklund DJ; Chase M; Naismith RT; Klawiter EC; Goodman AD; Coffey CS; Fox RJ Mult Scler; 2021 Aug; 27(9):1384-1390. PubMed ID: 33054533 [TBL] [Abstract][Full Text] [Related]
36. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis. Sellebjerg F; Royen L; Soelberg Sørensen P; Oturai AB; Jensen PEH Mult Scler; 2019 Oct; 25(11):1444-1451. PubMed ID: 30113249 [TBL] [Abstract][Full Text] [Related]
37. Clinical and MRI correlates of CSF neurofilament light chain levels in relapsing and progressive MS. Damasceno A; Dias-Carneiro RPC; Moraes AS; Boldrini VO; Quintiliano RPS; da Silva VAPG; Farias AS; Brandão CO; Damasceno BP; Dos Santos LMB; Cendes F Mult Scler Relat Disord; 2019 May; 30():149-153. PubMed ID: 30772673 [TBL] [Abstract][Full Text] [Related]
38. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027 [TBL] [Abstract][Full Text] [Related]
39. Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease. Peng L; Bi C; Xia D; Mao L; Qian H Mult Scler Relat Disord; 2019 May; 30():123-128. PubMed ID: 30771578 [TBL] [Abstract][Full Text] [Related]
40. A Comparison of Two Analytical Approaches for the Quantification of Neurofilament Light Chain, a Biomarker of Axonal Damage in Multiple Sclerosis. Pafiti A; Krashias G; Tzartos J; Tzartos S; Stergiou C; Gaglia E; Smoleski I; Christodoulou C; Pantzaris M; Lambrianides A Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445963 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]